29 research outputs found
ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΠΈ ΡΡΠ΅Π΄Π½Π΅-ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π°
Background. Psoriasis is a chronic inflammatory disease that associated with a decrease in life expectancy mostly due to cardiovascular disease. But prevalence of cardiovascular comorbidity in psoriasis patients has limited data. Objectives. To compare the prevalence of cardiovascular comorbidity in a hospital-treated cohort patients with severe psoriasis and psoriatic arthritis. Methods. 890 patients (M. - 516/F. - 347) with severe plaque psoriasis mean duration 25.7 Β± 16.6 years, mean age of patients were 51.9 Β± 11.6 years accordingly were included. Psoriasis patients with cardiovascular disease, including coronary heart disease, arterial hypertension, atherosclerosis and cerebrovascular accident were identify in the hospital Database reporting and coding by International Statistical Classification of Disease and Related Health Problems (ICD-10) between 2010-2015 years. M Β± m, t-test, (%) were calculated. All p < 0.05 were considered to indicate statistical significance. Results. Male and Female patients were at the same age. 303 out of 890 patients (34.0%) had psoriatic arthritis, 587 out of 890 patients (66.0%) had severe plaque psoriasis with mean PASI 49.4 Β± 0.5. 516 out of 890 patients (59.0%) had cardiovascular disease. Cardiovascular disease coding as I 00-I 99 were found significantly often in patients with psoriatic arthritis compare to patients with psoriasis - in 206 out of 303 patients (68.2%) and in 310 out of 587 patients (52.8%) accordingly (p < 0.05). Arterial hypertension coding as I 10-I 15 were found in significantly more cases in patients with psoriatic arthritis compare to patients with psoriasis - in 206 out of 303 patients (68.2%) and in 310 out of 587 patients (52.8%) accordingly (p < 0.05). Coronary heart disease and atherosclerosis coding as I 70 were found in significantly more cases in patients with psoriatic arthritis compare to patients with psoriasis - in 129 out of 303 patients (42.7%) and in 205 out of 587 patients (34.9%) accordingly (p < 0.05). Cerebrovascular accident coding as I 65 - I 66 were found in significantly more cases in patients with psoriatic arthritis compare to patients with psoriasis - in 50 out of 303 patients (16.6%) and in 64 out of 587 patients (10.9%) accordingly. Conclusions. Psoriatic arthritis and cardiovascular comorbidities are common for hospital-treated cohort patients. Patients with severe plaque psoriasis and psoriatic arthritis tend to suffer from cardiovascular disease and arterial hypertension.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. ΠΡΠΎΡΠΈΠ°Π·, ΠΊΡΠΎΠΌΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΊΠΎΠΆΠΈ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎΠΉ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ, Π² ΠΏΠ΅ΡΠ²ΡΡ ΠΎΡΠ΅ΡΠ΅Π΄Ρ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. ΠΠ°Π½Π½ΡΠ΅ ΠΎ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΏΡΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π΅ ΠΈ ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΌ Π°ΡΡΡΠΈΡΠ΅ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½Ρ. Π¦Π΅Π»Ρ: ΠΈΠ·ΡΡΠΈΡΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ ΠΈ ΡΡΡΡΠΊΡΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Ρ ΠΌΠΎΠ»ΠΎΠ΄ΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π° ΠΈ Ρ ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π°ΡΡΡΠΈΡΠΎΠΌ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ 890 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π° (ΠΌΡΠΆΡΠΈΠ½/ΠΆΠ΅Π½ΡΠΈΠ½ - 516/347, ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² 51,9 Β± 11,6 Π³ΠΎΠ΄Π°), ΡΡΠ΅Π΄Π½ΡΡ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΏΡΠΎΡΠΈΠ°Π·Π° 11,6 Β± 0,6 (ΠΌΠΈΠ½ΠΈΠΌΡΠΌ 1 Π³ΠΎΠ΄ - ΠΌΠ°ΠΊΡΠΈΠΌΡΠΌ 35 Π»Π΅Ρ), Π½Π°Ρ
ΠΎΠ΄ΠΈΠ²ΡΠΈΡ
ΡΡ Π½Π° ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π² Β«Π€ΠΈΠ»ΠΈΠ°Π»Π΅ ΠΠΎΡΠΎΠ»Π΅Π½ΠΊΠΎΒ» ΠΠΠΠ¦ΠΠ Π·Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ 2010-2015 Π³Π³. Π£ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° Π²ΠΊΠ»ΡΡΠ΅Π½Π½ΡΡ
Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ (71,3%) ΠΈΠ½Π΄Π΅ΠΊΡ ΡΡΠΆΠ΅ΡΡΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π° PASI ΡΠΎΡΡΠ°Π²ΠΈΠ» ΠΎΡ 45 Π΄ΠΎ 60 Π±Π°Π»Π»ΠΎΠ² (PASI 49,4 Β± 0,5). ΠΠ½Π°Π»ΠΈΠ· Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π²ΡΠΏΠΎΠ»Π½ΡΠ»ΠΈ Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΠΊΠΎΠ΄Π°ΠΌΠΈ ΠΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΠΎΠΉ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π±ΠΎΠ»Π΅Π·Π½Π΅ΠΉ 10 ΠΏΠ΅ΡΠ΅ΡΠΌΠΎΡΡΠ°. Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Ρ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½Π°Ρ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΡ (ΠΊΠΎΠ΄ ΠΠΠ - I10-I15), ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠ°Ρ Π±ΠΎΠ»Π΅Π·Π½Ρ ΡΠ΅ΡΠ΄ΡΠ° (I20-I25), Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ· (I70) ΠΈ ΡΠ΅ΡΠ΅Π±ΡΠΎΠ²Π°ΡΠΊΡΠ»ΡΡΠ½ΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ (I65-I66). ΠΠ»Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΡΡ ΡΠ°ΡΡΠ΅Ρ M, Ο, Β±m, Π₯ΠΈ-ΠΊΠ²Π°Π΄ΡΠ°Ρ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. Π£ 303 (34,0%) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π±ΡΠ» Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π½ ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΡΡΡΠΈΡ. ΠΠ±ΡΠ΅Π΅ ΡΠΈΡΠ»ΠΎ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΎ 516 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ (59,0%). Π ΡΡΡΡΠΊΡΡΡΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π°ΡΡΡΠΈΡΠΎΠΌ ΡΠ°ΡΠ΅ ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π»Π°ΡΡ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½Π°Ρ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΡ, ΡΠ΅ΠΌ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ - Ρ 68,2 ΠΈ Ρ 52,8% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠ°Ρ Π±ΠΎΠ»Π΅Π·Π½Ρ ΡΠ΅ΡΠ΄ΡΠ° ΠΈ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ· ΡΠ°ΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π»ΠΈΡΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π°ΡΡΡΠΈΡΠΎΠΌ, ΡΠ΅ΠΌ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ - Ρ 42,7 ΠΈ 34,9% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (p < 0,05). Π¦Π΅ΡΠ΅Π±ΡΠΎΠ²Π°ΡΠΊΡΠ»ΡΡΠ½ΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΡΠ°ΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π»Π°ΡΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π°ΡΡΡΠΈΡΠΎΠΌ, ΡΠ΅ΠΌ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ - Ρ 16,6 ΠΈ Ρ 10,9% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (p < 0,05). ΠΡΠ²ΠΎΠ΄Ρ. ΠΠ°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΡΠ΅Π³ΠΈΡΡΡΠΈΡΡΡΡΡΡ Π±ΠΎΠ»Π΅Π΅ ΡΠ΅ΠΌ Ρ ΠΏΠΎΠ»ΠΎΠ²ΠΈΠ½Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π° ΠΈ ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π°ΡΡΡΠΈΡΠΎΠΌ. Π‘ΡΠ΅Π΄ΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΡΠΎΠΉ Π³ΡΡΠΏΠΏΡ Π»ΠΈΠ΄ΠΈΡΡΠ΅Ρ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½Π°Ρ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΡ. ΠΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠ°Ρ Π±ΠΎΠ»Π΅Π·Π½Ρ ΡΠ΅ΡΠ΄ΡΠ° ΠΈ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ· ΡΠ°ΠΊΠΆΠ΅ Π²ΡΡΡΠ΅ΡΠ°ΡΡΡΡ Π²Π΅ΡΡΠΌΠ° ΡΠ°ΡΡΠΎ Π²ΠΎ Π²ΡΠ΅Ρ
Π³ΡΡΠΏΠΏΠ°Ρ
Π±ΠΎΠ»ΡΠ½ΡΡ
Using aknekutan in acne therapy: A new low-dose scheme
Systemic administration of isotretinoin holds the leading position among the modern methods of acne treatment. However, administration of high therapeutic doses of these drugs may lead to adverse side effects. The efficacy and safety of administration of low-doses of isotretinoin (Aknekutan) patients with mild, moderate and severe forms of acne resistant to standard treatment methods were assessed. The study involved 70 patients aged 18 to 38 years with papulopustular form of acne of varying severity. Patients were divided into three groups. The first group included 20 patients with mild form of acne; the second group, 47 patients with moderate form of acne; and the third group, 3 patients with severe acne. Patients in groups 1 and 2 received Aknekutan as monotherapy at a dose of 0.16β0.32 mg per kilogram body weight for 3β6 months (mean 4 months). Group 3 patients received macrolide antibiotics during first 10 days, followed by administration of isotretinoin at a dose of 0.32 mg per kilogram body weight. The biochemical parameters of blood and sebum secretion were measured in all patients before treatment and then monthly. Clinical cure was achieved in 61 patients; significant improvement, in 8 patients; improvement, in one patient. Therapy of severe acne with low doses of Aknekutan in third group patients showed lower efficacy. A decrease in side effects of low-dose isotretinoin administration was registered. Administration of low doses of isotretinoin to treat patients with mild and moderate acne improves efficacy and reduces the treatment duration, simplifies the treatment technique and reduces the medicamental and economic burden on patients. Β© 2014, Media Sphera Publishing Group. All rights reserved
Π Π°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·ΠΈΠ΅ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ
Rationale: Severe treatment-resistant psoriasis and comorbidities are on the rise.Aim: To evaluate the prevalence of comorbidities in aΒ hospital-based cohort of patients with severe psoriases.Materials and methods: We performed aΒ retrospective analysis of medical files of 890Β patients with moderate-to-severe plaque psoriasis (PASI > 10) treated in aΒ hospital from 2010 to 2015 (men, 516Β [58%], women, 374Β [42%]; mean age 51.9 Β± 11.6Β years; mean PASI, 44.3 Β± 7.8Β scores).Results: Comorbidities were found in 61%Β (543 / 890) of the patients with severe psoriasis, with cardiovascular disorders ranking first (59%, or 516 / 890) and gastrointestinal and hepatobiliary disorders ranking second (46,4%, or 413 / 890). Psoriatic arthritis was diagnosed in 34%Β (303 / 890) of the patients and other disorders of the musculoskeletal system unrelated to psoriasis in 19.8%Β (176 / 890). The proportion of diabetes was 15.4%Β (137 / 890).Conclusion: Psoriasis has aΒ high rate of comorbidities, in particular of cardiovascular disorders. It significantly deteriorates the course of psoriasis and its response to therapy, and in some cases may reduce the possibility of adequate anti-psoriatic treatment due to contraindications.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. ΠΡΠΌΠ΅ΡΠ°Π΅ΡΡΡ ΡΠΎΡΡ ΡΡΠΆΠ΅Π»ΡΡ
ΡΠΎΡΠΌ ΠΏΡΠΎΡΠΈΠ°Π·Π°, ΡΠΎΡΠΏΠΈΠ΄Π½ΡΡ
ΠΊΒ Π»Π΅ΡΠ΅Π½ΠΈΡ, Π°Β ΡΠ°ΠΊΠΆΠ΅ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ.Π¦Π΅Π»ΡΒ β ΠΈΠ·ΡΡΠΈΡΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ ΡΠΎΠΏΡΡΡΡΠ²ΡΡΡΠ΅ΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Π²Β Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΊΠΎΠ³ΠΎΡΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΒ ΡΡΠΆΠ΅Π»ΡΠΌ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈΒ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π΄Π°Π½Π½ΡΡ
ΠΈΡΡΠΎΡΠΈΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ 890Β Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΠΈΒ ΡΡΠ΅Π΄Π½Π΅ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ (PASI > 10), Π½Π°Ρ
ΠΎΠ΄ΠΈΠ²ΡΠΈΡ
ΡΡ Π½Π° ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π²Β ΠΏΠ΅ΡΠΈΠΎΠ΄ ΡΒ 2010 ΠΏΠΎ 2015 Π³. ΠΡΠΆΡΠΈΠ½ Π±ΡΠ»ΠΎ 516Β (58%), ΠΆΠ΅Π½ΡΠΈΠ½Β β 374Β (42%), ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΡΡΠ°Π²ΠΈΠ» 51,9 Β± 11,6Β Π³ΠΎΠ΄Π°, ΡΡΠ΅Π΄Π½Π΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ PASIΒ β 44,3 Β± 7,8.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π‘ΠΎΠΏΡΡΡΡΠ²ΡΡΡΠ°Ρ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ Π±ΡΠ»Π° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π½Π° ΡΒ 61%Β (543Β ΠΈΠ· 890) Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π°. ΠΒ ΡΡΡΡΠΊΡΡΡΠ΅ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΡΡΠΈ Π»ΠΈΠ΄ΠΈΡΡΡΡΠ΅Π΅ ΠΌΠ΅ΡΡΠΎ Π·Π°Π½ΠΈΠΌΠ°Π»ΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡΒ β 58%Β (516Β ΠΈΠ· 890) ΡΠ»ΡΡΠ°Π΅Π², Π΄Π°Π»Π΅Π΅ ΡΠ»Π΅Π΄ΠΎΠ²Π°Π»ΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΠΎ-ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠ° ΠΈΒ Π³Π΅ΠΏΠ°ΡΠΎΠ±ΠΈΠ»ΠΈΠ°ΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡΒ β 46,4%Β (413Β ΠΈΠ· 890). ΠΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΡΡΡΠΈΡ Π²ΡΡΠ²Π»ΡΠ»ΡΡ Π²Β 34%Β (ΡΒ 303 ΠΈΠ· 890) ΡΠ»ΡΡΠ°Π΅Π², Π΄ΡΡΠ³ΠΈΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΊΠΎΡΡΠ½ΠΎ-ΠΌΡΡΠ΅ΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ, Π½Π΅ ΡΠ²ΡΠ·Π°Π½Π½ΡΠ΅ ΡΒ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ,Β β Π²Β 19,8%Β (176 ΠΈΠ·Β 890). ΠΠΎΠ»Ρ ΡΠ°Ρ
Π°ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ°Π±Π΅ΡΠ° ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 15,4% (137 ΠΈΠ·Β 890).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΡΠ²Π»Π΅Π½Π° Π²ΡΡΠΎΠΊΠ°Ρ ΡΠ°ΡΡΠΎΡΠ° ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ°Π·Π° ΡΒ ΡΠΎΠΏΡΡΡΡΠ²ΡΡΡΠ΅ΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎ ΡΒ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. ΠΡΠΎ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΎΡΡΠ³ΠΎΡΠ°Π΅Ρ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠΈΠ°Π·Π°, ΡΡ
ΡΠ΄ΡΠ°Π΅Ρ ΠΎΡΠ²Π΅Ρ Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡ, Π²Β ΡΡΠ΄Π΅ ΡΠ»ΡΡΠ°Π΅Π² (Π² ΡΠ²ΡΠ·ΠΈ ΡΒ ΠΈΠΌΠ΅ΡΡΠΈΠΌΠΈΡΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΡΠΌΠΈ) ΡΠ½ΠΈΠΆΠ°Π΅Ρ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΏΠΎΠ»Π½ΠΎΡΠ΅Π½Π½ΠΎΠ³ΠΎ Π°Π½ΡΠΈΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ
Immunopathogenetic Comorbidity in Young Patients with Severe Plaque Psoriasis
Background Psoriasis is associated with multiple other comorbidities with a general inflammatory immune component, the most notable being cardiovascular (CVD) and metabolic disorders. But no study has been performed metabolic disorders in Russian population of Psoriasis (PsO) patients. Objectives To evaluate the prevalence of CV comorbidity, Obs, ThD and DM comorbidity in a hospital-based cohort of patients (pts) with severe PsO. Methods 330 patients (pts) (234 Male (M.)/96 Female (F.)), mean age 39.9 +/- 0.9/38.05 +/- 1.3 years accordingly, mean PASI 49.4 +/- 0.56, PsO duration 11.6 +/- 0.6 years were included. PsO pts with Endocrine, nutritional and metabolic diseases (E00-E90) (ENMD), including Obesity (Obs) and other hyperalimentation (E65-E68), diabetes mellitus (DM) (E10-E14) and PsO pts with cardiovascular disease (CVD), including coronary heart disease (CHID), arterial hypertension (AH), atherosclerosis and cerebrovascular accident (CVA) were identify in the hospital Database reporting and coding by International Statistical Classification of Disease and Related Health Problems (ICD-10) between 2010-2011 years. M +/- m, t-test, (%) were calculated. All p0.05). Conclusions ENMD and CV comorbidities are common for hospital-treated cohort pts with severe plaque PsO. Young M. pts with severe plaque PsO significantly often suffer from DM compared to F. pts. Young F. pts with severe plaque PsO tend to suffer from obesity and other hyperalimentation compared to M. pts. Young M. pts with severe plaque PsO tend to suffer from CVD and AH compared to F. Pts. Immune-mediated inflammation is the central actor in atherogenesis beyond all risk factors
ΠΠΊΡΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΈΡ ΠΠ»Π»ΠΎΠΏΠΎ - ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ°Π·Π½ΠΎΠ²ΠΈΠ΄Π½ΠΎΡΡΡ Π»Π°Π΄ΠΎΠ½Π½ΠΎ-ΠΏΠΎΠ΄ΠΎΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΡΡΡΠ»Π΅Π·Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ°Π·Π°?
Pustular palmar-plantar psoriasis has a number of clinical variants. Dermatologists describe it as independent diseases, for example, acrodermatitis continua suppurativa Hallopeau, etc. The aim of the study was a clinical and laboratory evaluation of two clinical cases: pustular palmar-plantar psoriasis and acrodermatitis Hallopeau and to analyze literature sources on this topic. Results. Clinical, laboratory and pathomorphological examination showed a commonality in the observed patients with pustular palmar-plantar psoriasis and acrodermatitis Hallopeau. A sufficient number of publications on the transformation of acrodermatitis into generalized pustular psoriasis also confirm this point of view. Conclusion. Thus, our clinical observations, the data of literature sources allow us to refer acrodermatitis Hallopeau to a separate form of pustular psoriasis.ΠΡΡΡΡΠ»Π΅Π·Π½ΡΠΉ Π»Π°Π΄ΠΎΠ½Π½ΠΎ-ΠΏΠΎΠ΄ΠΎΡΠ²Π΅Π½Π½ΡΠΉ ΠΏΡΠΎΡΠΈΠ°Π· ΠΈΠΌΠ΅Π΅Ρ ΡΡΠ΄ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ². Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ, Π½Π΅ΡΠ΅Π΄ΠΊΠΎ, Π΄Π΅ΡΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΎΠΏΠΈΡΡΠ²Π°ΡΡ ΠΈΡ
ΠΊΠ°ΠΊ ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΡΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, Π½Π°ΠΏΡΠΈΠΌΠ΅Ρ, Π°ΠΊΡΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΈΡ ΠΠ»Π»ΠΎΠΏΠΎ ΠΈ Π΄Ρ. Π¦Π΅Π»ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΎ ΠΏΡΠΎΠ²Π΅ΡΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ ΠΎΡΠ΅Π½ΠΊΡ Π΄Π²ΡΡ
Π½Π°Π±Π»ΡΠ΄Π°Π΅ΠΌΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ»ΡΡΠ°Π΅Π²: ΠΏΡΡΡΡΠ»Π΅Π·Π½ΠΎΠ³ΠΎ Π»Π°Π΄ΠΎΠ½Π½ΠΎ-ΠΏΠΎΠ΄ΠΎΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ°Π·Π° ΠΈ Π°ΠΊΡΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΈΡΠ° ΠΠ»Π»ΠΎΠΏΠΎ ΠΈ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΡΠ΅ ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΈ ΠΏΠΎ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ΅ΠΌΠ΅. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅, Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠ΅ ΠΈ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ ΠΎΠ±ΡΠ½ΠΎΡΡΡ Ρ Π½Π°Π±Π»ΡΠ΄Π°Π΅ΠΌΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΡΡΡΠ»Π΅Π·Π½ΠΎΠ³ΠΎ Π»Π°Π΄ΠΎΠ½Π½ΠΎ-ΠΏΠΎΠ΄ΠΎΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ°Π·Π° ΠΈ Π°ΠΊΡΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΈΡΠ° ΠΠ»Π»ΠΎΠΏΠΎ. ΠΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠΉ ΡΠΎΡΠΊΠΈ Π·ΡΠ΅Π½ΠΈΡ ΡΠ²Π»ΡΡΡΡΡ ΡΠ°ΠΊΠΆΠ΅ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠ΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΉ ΠΎ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΠΈ Π°ΠΊΡΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΈΡΠ° Π² Π³Π΅Π½Π΅ΡΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΉ ΠΏΡΡΡΡΠ»Π΅Π·Π½ΡΠΉ ΠΏΡΠΎΡΠΈΠ°Π·. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π½Π°ΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ, Π΄Π°Π½Π½ΡΠ΅ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΡΡ
ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ² ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΠΎΡΠ½Π΅ΡΡΠΈ Π°ΠΊΡΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΈΡ ΠΠ»Π»ΠΎΠΏΠΎ ΠΊ ΠΎΡΠ΄Π΅Π»ΡΠ½ΠΎΠΉ ΡΠΎΡΠΌΠ΅ ΠΏΡΡΡΡΠ»Π΅Π·Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ°Π·Π°
The pattern of cardiovascular comorbidity in patients with severe forms of psoriasis: Data of retrospective analysis of a hospital cohort
Psoriasis (Ps) and psoriatic arthritis (PsA) are, in addition to skin and osteoarticular lesions, accompanied by a variety of comorbidities, primarily cardiovascular diseases (CVDs), which contributes to shorter life expectancy by on an average of 5-7 years. There are scarce data on the prevalence and pattern of CVDs in a Russian cohort of patients with severe forms of Ps and PsA. Obtaining such information can contribute to the elaboration of programs for screening and prevention of CVDs in this patient group. Objective: to study the prevalence and pattern of CVDs in a hospital cohort of patients with severe forms of Ps and PsA. Subjects and methods. Medical records were retrospectively analyzed in 890 patients with severe forms of Ps (mean age, 51.9Β±11.6 years; mean Ps duration, 11.6Β±0.6 years); who had been treated at the Branch of the V.G. Korolenko Clinic, Moscow Research and Practical Center of Dermatovenereology and Cosmetology, in 2010 to 2015. The Psoriasis Area and Severity Index (PASI) averaged 49.4Β±0.5. The frequency of PsA was assessed by the code L40.5; that of SVDs was determined by the registered diagnoses in accordance with the codes of the International Classification of Diseases, 10th edition (ICD-10): hypertension (ICD-10 code I10-I15), coronary heart disease (CHD) (I20-I25), atherosclerosis (I70), and cerebrovascular disorders (I65-I66). Results and discussion. PsA was identified in 303 (34%) patients. There were a total of 516 (59%) patients with CVDs. Hypertension, CHD, atherosclerosis, and cerebrovascular disorders were more frequently recorded in patients with PsA than in those with PsA without arthritis. Conclusion. CVDs are recorded in more than half of the hospital cohort patients with severe forms of Ps. CVDs are more frequently recorded in PsA than in Ps without arthritis. Hypertension among the SVDs is a leader in its frequency in both groups; more than half of the patients were found to have CHD and atherosclerosis; cerebrovascular disorders were less common
ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°ΡΡΡΠΈΡΠ° Π±Π΅Π· ΠΊΠΎΠΆΠ½ΡΡ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ
Psoriatic arthritis occupies a special place among the severe disease forms, as it significantly worsens the life quality and physical function of patients. The disease is progressive and can lead to patient disability. The psoriatic arthritis prevalence in patients varies significantly and its precise assessment is difficult due to the minimal clinical manifestations of the disease onset, as well as psoriasis clinical manifestations in some patients (about 15%) only after the joint disease. Arising at any age, psoriatic arthritis often leads to functional limitation and expressed physical and psychological discomfort development in patients. If left untreated, persistent inflammation with progressive joint damage may develop in some patients, which can lead to severe functional limitations and disability. It is for this reason that early diagnosis by a rheumatologist and the selection of adequate therapy are crucial. Thus, psoriatic arthritis is an important medical and socio-economic problem, having an adverse impact on the physical and psycho-emotional health of patients, often at a young, working age.ΠΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΡΡΡΠΈΡ (ΠΡΠ) Π·Π°Π½ΠΈΠΌΠ°Π΅Ρ ΠΎΡΠΎΠ±ΠΎΠ΅ ΠΌΠ΅ΡΡΠΎ Π² ΡΡΠ΄Ρ ΡΡΠΆΠ΅Π»ΡΡ
ΡΠΎΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, Ρ. ΠΊ. ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΡΡ
ΡΠ΄ΡΠ°Π΅Ρ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΉ ΡΡΠ°ΡΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠ°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΡΡΠΈΠΌ ΠΈ ΠΌΠΎΠΆΠ΅Ρ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡΡ ΠΊ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΈΠ·Π°ΡΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
. Π Π°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ ΠΡΠ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π²Π°ΡΡΠΈΡΡΠ΅Ρ, ΠΈ ΡΠΎΡΠ½Π°Ρ Π΅Π΅ ΠΎΡΠ΅Π½ΠΊΠ° Π·Π°ΡΡΡΠ΄Π½ΠΈΡΠ΅Π»ΡΠ½Π° Π² ΡΠ²ΡΠ·ΠΈ Ρ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π² Π΄Π΅Π±ΡΡΠ΅, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΠ΅ΠΌ Ρ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
(ΠΎΠΊΠΎΠ»ΠΎ 15%) ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ ΠΏΡΠΎΡΠΈΠ°Π·Π° ΡΠΎΠ»ΡΠΊΠΎ ΠΏΠΎΡΠ»Π΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΡΡΡΡΠ°Π²ΠΎΠ². ΠΠΎΠ·Π½ΠΈΠΊΠ°Ρ Π² Π»ΡΠ±ΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅, ΠΡΠ ΡΠ°ΡΡΠΎ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, ΡΠ°Π·Π²ΠΈΡΠΈΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠ³ΠΎ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ ΠΏΡΠΈΡ
ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄ΠΈΡΠΊΠΎΠΌΡΠΎΡΡΠ°. ΠΡΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Ρ ΡΠ°ΡΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΌΠΎΠΆΠ΅Ρ ΡΠ°Π·Π²ΠΈΡΡΡΡ ΡΡΠΎΠΉΠΊΠΎΠ΅ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΠ΅ Ρ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΡΡΠΈΠΌ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ΠΌ ΡΡΡΡΠ°Π²ΠΎΠ², ΡΡΠΎ ΠΌΠΎΠΆΠ΅Ρ ΠΏΡΠΈΠ²Π΅ΡΡΠΈ ΠΊ ΡΠ΅ΡΡΠ΅Π·Π½ΡΠΌ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΡΠΌ ΠΈ ΠΈΠ½Π²Π°Π»ΠΈΠ΄Π½ΠΎΡΡΠΈ. ΠΠΌΠ΅Π½Π½ΠΎ ΠΏΠΎ ΡΡΠΎΠΉ ΠΏΡΠΈΡΠΈΠ½Π΅ ΡΠ°Π½Π½ΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° Ρ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³Π° ΠΈ ΠΏΠΎΠ΄Π±ΠΎΡ Π°Π΄Π΅ΠΊΠ²Π°ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠΌΠ΅ΡΡ ΡΠ΅ΡΠ°ΡΡΠ΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, ΠΡΠ ΡΠ²Π»ΡΠ΅ΡΡΡ Π²Π°ΠΆΠ½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΈ ΡΠΎΡΠΈΠ°Π»ΡΠ½ΠΎ-ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΎΠΉ, ΠΎΠΊΠ°Π·ΡΠ²Π°Ρ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈ ΠΏΡΠΈΡ
ΠΎΡΠΌΠΎΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ΅ Π·Π΄ΠΎΡΠΎΠ²ΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π½Π΅ΡΠ΅Π΄ΠΊΠΎ Π² ΠΌΠΎΠ»ΠΎΠ΄ΠΎΠΌ, ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅
Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° Dermatology Life Quality Index Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·Π°ΠΌΠΈ
Objectives: compare the quality of life index of patients with severe forms of psoriasis (PsO) with psoriatic arthritis patientsβ index. Methods. 187 (100%) patients suffering from chronical dermatitis Male-105/female - 82) were analyzed. The quality of life was assessed using the Dermatology Life Quality Index (DLQI) questionnaire. Statistical processing of the data was carried out using the Excel analysis package. All p<0.05 were considered to indicate statistical significance. Results. The total score DLQI in the group was 17,8Β±5,2 (n=187). Conclusions. The total score DLQI was high in patients with chronical dermatitis. This result revealed the existence of an inferior quality of life for the patients with comorbidity disease, compared with pts without comorbidity disease.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ - ΡΡΠ°Π²Π½ΠΈΡΡ ΠΠ΅ΡΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΈΠ½Π΄Π΅ΠΊΡ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ (DLQI) Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·Π°ΠΌΠΈ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠ½ΠΎΠ²Π½ΡΡ Π³ΡΡΠΏΠΏΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 187 (100%) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΡΡΠ°Π΄Π°ΡΡΠΈΡ
ΡΡΠΆΠ΅Π»ΡΠΌΠΈ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·Π°ΠΌΠΈ 105 ΠΌΡΠΆΡΠΈΠ½ / 82 ΠΆΠ΅Π½ΡΠΈΠ½Ρ, Π½Π°Ρ
ΠΎΠ΄ΠΈΠ²ΡΠΈΡ
ΡΡ Π½Π° ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π² Β«Π€ΠΈΠ»ΠΈΠ°Π»Π΅ ΠΠΎΡΠΎΠ»Π΅Π½ΠΊΠΎΒ» ΠΠΠΠ¦ΠΠ Π·Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ 2017 Π³.. ΠΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΎΡΡ ΠΏΠΎ ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊΡ ΠΠ½Π΄Π΅ΠΊΡ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
(Dermatology Life Quality Index, DLQI). ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ°ΡΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈΡΡ ΡΠΎΠ³Π»Π°ΡΠ½ΠΎ ΡΠΊΠ°Π»Π΅ ΠΈΠ½ΡΠ΅ΡΠΏΡΠ΅ΡΠ°ΡΠΈΠΈ. ΠΠ»Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΡΡ ΡΠ°ΡΡΠ΅Ρ M, Ο, Β±m, Π₯ΠΈ-ΠΊΠ²Π°Π΄ΡΠ°Ρ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π‘ΡΠ΅Π΄Π½Π΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ DLQI Ρ Π²ΡΠ΅Ρ
ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΎ 17,8Β±5,2 (n=187), ΡΠΎ Π΅ΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ ΠΎΡΠ΅Π½Ρ ΡΠΈΠ»ΡΠ½ΠΎ Π²Π»ΠΈΡΠ»ΠΎ Π½Π° ΠΆΠΈΠ·Π½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΈ ΡΠ½ΠΈΠΆΠ°Π»ΠΎ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ. ΠΡΠ²ΠΎΠ΄Ρ. ΠΡΠ΅ Π±ΠΎΠ»ΡΠ½ΡΠ΅ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·Π°ΠΌΠΈ, Π½Π°Ρ
ΠΎΠ΄ΠΈΠ²ΡΠΈΠ΅ΡΡ Π½Π° ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π² Β«Π€ΠΈΠ»ΠΈΠ°Π»Π΅ ΠΠΎΡΠΎΠ»Π΅Π½ΠΊΠΎΒ» ΠΠΠΠ¦ΠΠ Π² 2017Π³, ΠΈΠΌΠ΅Π»ΠΈ Π²ΡΡΠΎΠΊΠΎΠ΅ ΡΡΠ΅Π΄Π½Π΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ DLQI, ΡΡΠΎ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎΡΠ΅Π½Ρ ΡΠΈΠ»ΡΠ½ΠΎΠΌΡ Π²Π»ΠΈΡΠ½ΠΈΡ ΠΊΠΎΠΆΠ½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π½Π° ΠΆΠΈΠ·Π½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°
ΠΠ»ΠΈΡΠ½ΠΈΠ΅ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠΆΠ΅Π»ΡΡ ΡΠΎΡΠΌ ΠΏΡΠΎΡΠΈΠ°Π·Π° Π°Π½ΡΠΈΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ°ΠΌΠΈ Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²
Relevance. Psoriasis is an immune-mediated skin disease that affects 2-4 % of the worldβs population. Often, patients with severe forms of psoriasis are prescribed antitumor therapy. Systemic treatment, including methotrexate, is associated with hepatotoxicity and hematologic toxicity. Structural and functional damage to the liver, as well as changes of a different nature in the blood, are the most common and serious complications of immunosuppressive therapy. Objective: to determine the effect on aminotransferase parameters in patients with severe forms of psoriasis who receive systemic therapy, and to compare leukogram parameters in these patients depending on age. Material and methods. The study involved 164 (100 %) patients suffering from severe PS (92 men (56.8 %) / 72 women (44.4 %)). Only skin manifestations of PS were in 137 (83.5 %) of 164 people, PsA was recorded in 27 (16.4 %) of 164 patients. The average age of patients with Ps was 42.3 Β±14.6 years, with PsA - 54.0 Β±14.0 years. Results. The average value of ALT in patients with Ps is 29.6 (Β±16.3). The average AST value is 31.2 (Β±23.9). The level of leukocytes in patients with Ps only was 6.7 Β±2.3 * 109/l, ESR - 14.4 Β±10.6; neutrophils - 60.8 Β±10.4%; lymphocytes - 28.1 Β±8.8%. The average value of ALT in patients with PsA is 30.66 (Β±22.2). The average AST value is 31.2 (Β±16.6). The level of leukocytes in patients with PsA was 7.8 Β±2.4 * 109 / l; ESR - 14.3 Β±10.5; neutrophils - 60.0 Β±10.2 %; lymphocytes - 28.5 Β±8.9%. Conclusions. There is a significant increase in aminotransferases and changes in leukogram in patients with severe forms of psoriasis. Long-term use of methotrexate has the effect, patients with risk factors have the most influence, the most important of these risk factors are alcohol consumption, liver disease, the total and gradually increasing dose of the drug, the age of patients. The greatest effect was found in patients with PsA receiving systemic therapy and suffering from chronic alcoholism.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. ΠΡΠΎΡΠΈΠ°Π· (ΠΡ) ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΠΎΠΏΠΎΡΡΠ΅Π΄ΠΎΠ²Π°Π½Π½ΡΠΌ Π·Π°Π±ΠΎ Π»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠΆΠΈ, ΠΊΠΎΡΠΎΡΠΎΠ΅ Π·Π°ΡΡΠ°Π³ΠΈΠ²Π°Π΅Ρ 2-4 % ΠΌΠΈΡΠΎΠ²ΠΎΠ³ΠΎ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ. ΠΠ΅ΡΠ΅Π΄ΠΊΠΎ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Ρ ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π° Π½Π°Π·Π½Π°ΡΠ°Π΅ΡΡΡ ΡΠΈΡΡΠ΅ΠΌΠ½Π°Ρ ΡΠΈΡΠΎΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ. Π§Π°ΡΠ΅ Π²ΡΠ΅Π³ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ, ΠΎΡΠ½ΠΎΡΡΡΠΈΠ΅ΡΡ ΠΊ Π³ΡΡΠΏΠΏΠ΅ Π°Π½ΡΠΈΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠΎΠ² (Π½Π°ΠΏΡΠΈΠΌΠ΅Ρ, ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°Ρ). Π‘ΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅, Π²ΠΊΠ»ΡΡΠ°ΡΡΠ΅Π΅ ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°Ρ, ΡΠ²ΡΠ·Π°Π½ΠΎ Ρ Π³Π΅ΠΏΠ°ΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΡΡ ΠΈ Π³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΡΡ. Π‘ΡΡΡΠΊΡΡΡΠ½ΠΎ-ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ³ΠΎ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ° Π² ΠΊΡΠΎΠ²ΠΈ ΡΠ²Π»ΡΡΡΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌΠΈ ΠΈ ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡΠΌΠΈ ΡΠΈΡΠΎΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠΎΠΌ Π½Π° ΡΡΠ½ΠΊΡΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π»Π΅ΠΉΠΊΠΎΠ³ΡΠ°ΠΌΠΌΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π°. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΡΠΏΠΏΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 164 (100 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°, ΡΡΡΠ°Π΄Π°ΡΡΠΈΡ
ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΡ (92 ΠΌΡΠΆΡΠΈΠ½ (56,8 %)/ 72 ΠΆΠ΅Π½ΡΠΈΠ½ (44,4 %)). Π’ΠΎΠ»ΡΠΊΠΎ ΠΊΠΎΠΆΠ½ΡΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΠΡ Π±ΡΠ»ΠΈ Ρ 137 (83,5 %) ΠΈΠ· 164 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ, ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΡΡΡΠΈΡ (ΠΡΠ) ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π»ΡΡ Ρ 27(16,4%) ΠΈΠ· 164 Π±ΠΎΠ»ΡΠ½ΡΡ
. Π‘ΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠΎΠ»ΡΠΊΠΎ ΠΊΠΎΠΆΠ½ΡΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ ΠΡ ΡΠΎΡΡΠ°Π²ΠΈΠ» 42,3 Β±14,6 Π»Π΅Ρ, Ρ ΠΡΠ - 54,0 Β±14,0 Π»Π΅Ρ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π‘ΡΠ΅Π΄Π½Π΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΠΠ’ (Π°Π»Π°Π½ΠΈΠ½Π°ΠΌΠΈΠ½ΠΎΡΡΠ°Π½ΡΡΠ΅ΡΠ°Π·Π°) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΎ 29,6 (Β±16,3). Π‘ΡΠ΅Π΄Π½Π΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΠ‘Π’ (Π°ΡΠΏΠ°ΡΡΠ°ΡΠ°ΠΌΠΈΠ½ΠΎΡΡΠ°Π½ΡΡΠ΅ΡΠ°Π·Π°) - 31,2 (Β±23,9). Π‘ΡΠ΅Π΄Π½ΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ² Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΠ»ΡΠΊΠΎ Ρ ΠΊΠΎΠΆΠ½ΡΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ ΠΡ ΡΠΎΡΡΠ°Π²ΠΈΠ» 6,7 Β±2,3 * 109/Π», Π‘ΠΠ -14,4 Β±10,6; ΡΡΠ΅Π΄Π½Π΅Π΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ Π½Π΅ΠΉΡΡΠΎΡΠΈΠ»ΠΎΠ² Π±ΡΠ»ΠΎ 60,8 Β±10,4%; Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² - 28,1Β±8,8%. Π‘ΡΠ΅Π΄Π½Π΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΠΠ’ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΡΠ Π±ΡΠ»ΠΎ 30,66 (Β±22,2). Π‘ΡΠ΅Π΄Π½Π΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΠ‘Π’ - 31,2 (Β±16,6). Π£ΡΠΎΠ²Π΅Π½Ρ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ² Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΡΠ ΡΠΎΡΡΠ°Π²ΠΈΠ» 7,8 Β±2,4 * 109/Π»; Π‘ΠΠ - 14,3 Β±10,5; ΡΡΠΎΠ²Π΅Π½Ρ Π½Π΅ΠΉΡΡΠΎΡΠΈΠ»ΠΎΠ² - 60,0 Β±10,2 %; Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² - 28,5 Β±8,9 %. ΠΡΠ²ΠΎΠ΄Ρ. Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΡ ΠΎΡΠΌΠ΅ΡΠ°Π΅ΡΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Π΅ΠΉ Π°ΠΌΠΈΠ½ΠΎΡΡΠ°Π½ΡΡΠ΅ΡΠ°Π· ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π»Π΅ΠΉΠΊΠΎΠ³ΡΠ°ΠΌΠΌΡ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π½ΠΎΡΠΌΠΎΠΉ. ΠΡΠΎ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΡΠ²ΡΠ·Π°Π½ΠΎ ΠΊΠ°ΠΊ Ρ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΠΏΡΠΈΠ΅ΠΌΠΎΠΌ ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠ°, ΡΠ°ΠΊ ΠΈ Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ ΡΠ°ΠΊΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΠΈΡΠΊΠ°, ΠΊΠ°ΠΊ ΡΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΠ΅ Π°Π»ΠΊΠΎΠ³ΠΎΠ»Ρ ΠΈ Π½Π°Π»ΠΈΡΠΈΠ΅ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ Π³Π΅ΠΏΠ°ΡΠΎΠ±ΠΈΠ»ΠΈΠ°ΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. ΠΠ°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π²ΡΡΠ²Π»Π΅Π½Ρ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΡΠ, ΠΏΠΎΠ»ΡΡΠ°ΡΡΠΈΡ
ΡΠΈΡΡΠ΅ΠΌΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΈ Π·Π»ΠΎΡΠΏΠΎΡΡΠ΅Π±Π»ΡΡΡΠΈΡ
Π°Π»ΠΊΠΎΠ³ΠΎΠ»Π΅ΠΌ
ΠΠΊΡΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΈΡ ΠΠ»Π»ΠΎΠΏΠΎ - ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ°Π·Π½ΠΎΠ²ΠΈΠ΄Π½ΠΎΡΡΡ Π»Π°Π΄ΠΎΠ½Π½ΠΎ-ΠΏΠΎΠ΄ΠΎΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΡΡΡΠ»Π΅Π·Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ°Π·Π°?
Pustular palmar-plantar psoriasis has a number of clinical variants. Dermatologists describe it as independent diseases, for example, acrodermatitis continua suppurativa Hallopeau, etc. The aim of the study was a clinical and laboratory evaluation of two clinical cases: pustular palmar-plantar psoriasis and acrodermatitis Hallopeau and to analyze literature sources on this topic. Results. Clinical, laboratory and pathomorphological examination showed a commonality in the observed patients with pustular palmar-plantar psoriasis and acrodermatitis Hallopeau. A sufficient number of publications on the transformation of acrodermatitis into generalized pustular psoriasis also confirm this point of view. Conclusion. Thus, our clinical observations, the data of literature sources allow us to refer acrodermatitis Hallopeau to a separate form of pustular psoriasis.ΠΡΡΡΡΠ»Π΅Π·Π½ΡΠΉ Π»Π°Π΄ΠΎΠ½Π½ΠΎ-ΠΏΠΎΠ΄ΠΎΡΠ²Π΅Π½Π½ΡΠΉ ΠΏΡΠΎΡΠΈΠ°Π· ΠΈΠΌΠ΅Π΅Ρ ΡΡΠ΄ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ². Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ, Π½Π΅ΡΠ΅Π΄ΠΊΠΎ, Π΄Π΅ΡΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΎΠΏΠΈΡΡΠ²Π°ΡΡ ΠΈΡ
ΠΊΠ°ΠΊ ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΡΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, Π½Π°ΠΏΡΠΈΠΌΠ΅Ρ, Π°ΠΊΡΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΈΡ ΠΠ»Π»ΠΎΠΏΠΎ ΠΈ Π΄Ρ. Π¦Π΅Π»ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΎ ΠΏΡΠΎΠ²Π΅ΡΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ ΠΎΡΠ΅Π½ΠΊΡ Π΄Π²ΡΡ
Π½Π°Π±Π»ΡΠ΄Π°Π΅ΠΌΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ»ΡΡΠ°Π΅Π²: ΠΏΡΡΡΡΠ»Π΅Π·Π½ΠΎΠ³ΠΎ Π»Π°Π΄ΠΎΠ½Π½ΠΎ-ΠΏΠΎΠ΄ΠΎΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ°Π·Π° ΠΈ Π°ΠΊΡΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΈΡΠ° ΠΠ»Π»ΠΎΠΏΠΎ ΠΈ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΡΠ΅ ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΈ ΠΏΠΎ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ΅ΠΌΠ΅. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅, Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠ΅ ΠΈ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ ΠΎΠ±ΡΠ½ΠΎΡΡΡ Ρ Π½Π°Π±Π»ΡΠ΄Π°Π΅ΠΌΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΡΡΡΠ»Π΅Π·Π½ΠΎΠ³ΠΎ Π»Π°Π΄ΠΎΠ½Π½ΠΎ-ΠΏΠΎΠ΄ΠΎΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ°Π·Π° ΠΈ Π°ΠΊΡΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΈΡΠ° ΠΠ»Π»ΠΎΠΏΠΎ. ΠΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠΉ ΡΠΎΡΠΊΠΈ Π·ΡΠ΅Π½ΠΈΡ ΡΠ²Π»ΡΡΡΡΡ ΡΠ°ΠΊΠΆΠ΅ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠ΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΉ ΠΎ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΠΈ Π°ΠΊΡΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΈΡΠ° Π² Π³Π΅Π½Π΅ΡΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΉ ΠΏΡΡΡΡΠ»Π΅Π·Π½ΡΠΉ ΠΏΡΠΎΡΠΈΠ°Π·. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π½Π°ΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ, Π΄Π°Π½Π½ΡΠ΅ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΡΡ
ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ² ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΠΎΡΠ½Π΅ΡΡΠΈ Π°ΠΊΡΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΈΡ ΠΠ»Π»ΠΎΠΏΠΎ ΠΊ ΠΎΡΠ΄Π΅Π»ΡΠ½ΠΎΠΉ ΡΠΎΡΠΌΠ΅ ΠΏΡΡΡΡΠ»Π΅Π·Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ°Π·Π°